← Leaderboards
Steven H Liang
Emory University
$32,638,939
Attributed
$33,797,058
Total exposure
20
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.7M · FY2014–25$10M$7.5M$5M$2.5M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,797,058 · 20
By mechanism
R01$22,952,711 · 9
RF1$4,656,983 · 2
R21$1,727,693 · 4
R61$1,587,081 · 1
K01$927,050 · 1
R33$850,765 · 1
Top collaborators
- James J Lah3 shared
Most similar at Emory University
Same institution · by research overlap
- Larry J Young$28,392,997
- Lisa A McGraw$245,020
- Mark E Wilson$24,274,420
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainImageUnited StatesPositron-Emission TomographyDesignIn VivoKineticsImaging DeviceImaging StudyEvaluationBindingMonitorBiochemical ProcessMouse ModelLigandsIn VitroUptakeNonhuman PrimateRodentPharmaceutical PreparationsRadiolabeledLabelSite
Grant awards (57)
PET ligand discovery for arginine vasopressin$1,178,805
R01 · FY2025 · MH · contact PI
Poly (ADP-ribose) polymerase ligand discovery for Alzheimer's disease$782,495
R01 · FY2025 · AG · contact PI
AMPAR ligand discovery for Alzheimer's disease$766,848
R01 · FY2025 · AG · contact PI
Subtype-selective NMDA ligands for Alzheimer's Disease$762,049
R01 · FY2025 · AG · contact PI
Translation of GluN2B-selective PET radiopharmaceuticals in Alzheimers patients$755,607
R01 · FY2025 · AG · contact PI
Subtype-selective phosphodiesterase PET ligands$747,136
R01 · FY2025 · AG · contact PI
Ligand discovery for delineating cholesterol homeostasis in the brain$744,264
R01 · FY2025 · AG · contact PI
PET ligand discovery for arginine vasopressin$1,188,059
R01 · FY2024 · MH · contact PI
AMPAR ligand discovery for Alzheimer's disease$782,498
R01 · FY2024 · AG · contact PI
Translation of GluN2B-selective PET radiopharmaceuticals in Alzheimers patients$778,137
R01 · FY2024 · AG · contact PI
Subtype-selective phosphodiesterase PET ligands$777,332
R01 · FY2024 · AG · contact PI
Subtype-selective NMDA ligands for Alzheimer's Disease$772,160
R01 · FY2024 · AG · contact PI
Subtype-Selective Metabotropic Glutamate Receptor PET Ligands$770,694
R61 · FY2024 · NS · contact PI
Ligand discovery for delineating cholesterol homeostasis in the brain$767,614
R01 · FY2024 · AG · contact PI
micro-PET/CT system for preclinical molecular imaging$600,000
S10 · FY2024 · OD · contact PI
PET imaging of ionotropic glutamate receptor signaling in Alzheimer's disease$195,625
R21 · FY2024 · AG · contact PI
Glycogen synthase kinase 3 ligand discovery for Alzheimerâs disease$2,323,421
RF1 · FY2023 · AG · contact PI
PET ligand discovery for arginine vasopressin$1,214,143
R01 · FY2023 · MH · contact PI
Subtype-Selective Metabotropic Glutamate Receptor PET Ligands$816,387
R61 · FY2023 · NS · contact PI
Translation of GluN2B-selective PET radiopharmaceuticals in Alzheimers patients$782,495
R01 · FY2023 · AG · contact PI
Subtype-selective phosphodiesterase PET ligands$782,492
R01 · FY2023 · AG · contact PI
Subtype-selective NMDA ligands for Alzheimer's Disease$780,998
R01 · FY2023 · AG · contact PI
Ligand discovery for delineating cholesterol homeostasis in the brain$774,780
R01 · FY2023 · AG · contact PI
PET imaging of ionotropic glutamate receptor signaling in Alzheimer's disease$234,750
R21 · FY2023 · AG · contact PI
PET ligand discovery for arginine vasopressin$1,043,141
R01 · FY2022 · MH · contact PI
Subtype-selective NMDA ligands for Alzheimer's Disease$782,248
R01 · FY2022 · AG · contact PI
Ligand discovery for delineating cholesterol homeostasis in the brain$760,111
R01 · FY2022 · AG · contact PI
PET imaging for neuroimmune function in Alzheimer's disease$430,375
R21 · FY2022 · AG · contact PI
Supplement for Ligand discovery for delineating cholesterol homeostasis in the brain$349,250
R01 · FY2022 · AG · contact PI
PET Imaging for neuroinflammation in Alzheimer's disease$195,625
R21 · FY2022 · AG · contact PI
Ligand discovery for delineating cholesterol homeostasis in the brain$39,125
R01 · FY2022 · AG · contact PI
AMPAR ligand discovery for Alzheimer's disease$1,949,397
RF1 · FY2021 · AG · contact PI
Ligand discovery for delineating cholesterol homeostasis in the brain$808,990
R01 · FY2021 · AG · contact PI
In vivo Probe for ionotropic glutamate signaling system: AMPA receptors$788,641
R01 · FY2021 · MH · contact PI
AMPAR ligand discovery for Alzheimer's disease$384,165
RF1 · FY2021 · AG · contact PI
PET Imaging for neuroinflammation in Alzheimer's disease$246,560
R21 · FY2021 · AG · contact PI
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid Signaling$17,526
R33 · FY2021 · DA · contact PI
In vivo Probe for ionotropic glutamate signaling system: AMPA receptors$1
R01 · FY2021 · MH · contact PI
In vivo Probe for ionotropic glutamate signaling system: AMPA receptors$731,804
R01 · FY2020 · MH · contact PI
PET ligand development for mGlu2 based on negative allosteric modulators$625,674
R01 · FY2020 · MH · contact PI
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid Signaling$416,642
R33 · FY2020 · DA · contact PI
AMPAR-targeted PET imaging study of Alzheimer's disease$190,902
R01 · FY2020 · MH · contact PI
MAGL PET tracer-guided prognosis and neuroprotective therapy for Alzheimer's disease$165,552
R03 · FY2020 · AG · contact PI
MAGL PET tracer-guided prognosis and neuroprotective therapy for Alzheimer's disease$163,671
R03 · FY2020 · AG · contact PI
PET ligand development for mGlu2 based on negative allosteric modulators$145,000
R01 · FY2020 · MH · contact PI
In vivo Probe for ionotropic glutamate signaling system: AMPA receptors$719,969
R01 · FY2019 · MH · contact PI
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid Signaling$416,597
R33 · FY2019 · DA · contact PI
PET ligand development for mGlu2 based on negative allosteric modulators$406,367
R01 · FY2019 · MH · contact PI
MAGL PET tracer-guided prognosis and neuroprotective therapy for Alzheimer's disease$165,552
R03 · FY2019 · AG · contact PI
PET ligand development for mGlu2 based on negative allosteric modulators$423,576
R01 · FY2018 · MH · contact PI
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid Signaling$211,011
R21 · FY2018 · DA · contact PI
New PET tracers for neuroimaging of FAAH in endocannabinoid signaling$185,410
K01 · FY2018 · DA · contact PI
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid Signaling$213,747
R21 · FY2017 · DA · contact PI
New PET tracers for neuroimaging of FAAH in endocannabinoid signaling$185,410
K01 · FY2017 · DA · contact PI
New PET tracers for neuroimaging of FAAH in endocannabinoid signaling$185,410
K01 · FY2016 · DA · contact PI
New PET tracers for neuroimaging of FAAH in endocannabinoid signaling$185,410
K01 · FY2015 · DA · contact PI
New PET tracers for neuroimaging of FAAH in endocannabinoid signaling$185,410
K01 · FY2014 · DA · contact PI